SG11202113265PA - Triple pharmaceutical composition for proteinaceous infection - Google Patents

Triple pharmaceutical composition for proteinaceous infection

Info

Publication number
SG11202113265PA
SG11202113265PA SG11202113265PA SG11202113265PA SG11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA
Authority
SG
Singapore
Prior art keywords
proteinaceous
infection
pharmaceutical composition
triple
triple pharmaceutical
Prior art date
Application number
SG11202113265PA
Other languages
English (en)
Inventor
Joshua O Atiba
Original Assignee
Joshua O Atiba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/504,723 external-priority patent/US20200000829A1/en
Application filed by Joshua O Atiba filed Critical Joshua O Atiba
Publication of SG11202113265PA publication Critical patent/SG11202113265PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11202113265PA 2019-06-14 2020-06-15 Triple pharmaceutical composition for proteinaceous infection SG11202113265PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962861855P 2019-06-14 2019-06-14
US16/504,723 US20200000829A1 (en) 2018-06-27 2019-07-08 Therapy and prevention of prion protein complex infections
US16/565,242 US10729705B2 (en) 2018-06-27 2019-09-09 Therapy and prevention of prion protein complex infections in non-human animals
PCT/US2020/037787 WO2020252475A1 (fr) 2019-06-14 2020-06-15 Composition pharmaceutique triple pour une infection par les protéines

Publications (1)

Publication Number Publication Date
SG11202113265PA true SG11202113265PA (en) 2021-12-30

Family

ID=73782140

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113265PA SG11202113265PA (en) 2019-06-14 2020-06-15 Triple pharmaceutical composition for proteinaceous infection

Country Status (9)

Country Link
EP (1) EP3982956B1 (fr)
JP (1) JP2022537132A (fr)
KR (1) KR20220020832A (fr)
CN (1) CN114007609A (fr)
BR (1) BR112021025253A2 (fr)
CA (1) CA3142164A1 (fr)
MX (1) MX2021015266A (fr)
SG (1) SG11202113265PA (fr)
WO (1) WO2020252475A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
EP1558268A4 (fr) * 2002-09-17 2008-09-17 Univ New York Procedes pour traiter les alterations de la memoire liees a l'age (aami), les deficits cognitifs legers (mci) et les demences au moyen d'inhibiteurs du cycle cellulaire
JP2007532624A (ja) * 2004-04-14 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アルツハイマー病の治療のための療法組合せ
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
WO2015037023A1 (fr) * 2014-08-18 2015-03-19 Silvestri Fabrizio De Utilisation sous forme de pilules/comprimés/capsules de minocycline, acicloguanosine, atorvastatine et vitamine d dans le traitement de l'arthrite rhumatoïde
DE102016208567A1 (de) * 2016-05-19 2017-11-23 Heraeus Medical Gmbh Polymerlösung zur Viscosupplementation
US10350226B1 (en) * 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections

Also Published As

Publication number Publication date
WO2020252475A1 (fr) 2020-12-17
JP2022537132A (ja) 2022-08-24
EP3982956B1 (fr) 2024-06-12
BR112021025253A2 (pt) 2022-04-12
EP3982956A1 (fr) 2022-04-20
CA3142164A1 (fr) 2020-12-17
MX2021015266A (es) 2022-01-18
EP3982956A4 (fr) 2023-05-03
KR20220020832A (ko) 2022-02-21
CN114007609A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
EP3817722A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
EP4045480A4 (fr) Formulations pharmaceutiques
GB202008961D0 (en) Pharmaceutical composition
EP3946316A4 (fr) Compositions pharmaceutiques de cannabidiol
GB201911517D0 (en) Pharmaceutical composition
EP3868371A4 (fr) Nouvelle composition pharmaceutique
IL290469A (en) Oral pharmaceutical preparation
EP3881841A4 (fr) Composition pharmaceutique
EP3984549A4 (fr) Composition médicinale
SG11202113265PA (en) Triple pharmaceutical composition for proteinaceous infection
EP3949952A4 (fr) Composition médicinale
EP4081251A4 (fr) Compositions pharmaceutiques
EP3914234A4 (fr) Compositions pharmaceutiques
EP3964264A4 (fr) Nouvelle composition pharmaceutique
EP3950058A4 (fr) Composition pharmaceutique présentant une stabilité améliorée
EP4011393A4 (fr) Agent pharmaceutique pour administration transmucosale
EP3920909A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
EP3845230A4 (fr) Composition pharmaceutique pour administration par voie orale
HUE064916T2 (hu) Gyógyászati készítmény
EP3806838A4 (fr) Compositions pharmaceutiques comprenant des dérivés de poh
EP3841108A4 (fr) Compositions pharmaceutiques comprenant des peptides favorisant l'intégration
EP3746080A4 (fr) Formulations pharmaceutiques
EP4066852A4 (fr) Composition pharmaceutique
EP4032535A4 (fr) Composition pharmaceutique
EP3991750A4 (fr) Composition pharmaceutique